Type-2 diabetes drug significantly reduces hospitalisations and deaths from heart failure
Findings from a large clinical trial known as EMPA-REG OUTCOME were reported at the American Heart Association annual conference; they demonstrate for the first time that a type-2 diabetes drug, Jardiance, reduces risk of heart failure.
EurekAlert
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
More News: Cardiology | Clinical Trials | Conferences | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Failure | Jardiance